Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept
10.1007/s13139-017-0508-3
- Author:
Richard P BAUM
1
;
Thomas LANGBEIN
;
Aviral SINGH
;
Mostafa SHAHINFAR
;
Christiane SCHUCHARDT
;
Gerd Fabian VOLK
;
Harshad KULKARNI
Author Information
1. Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany. Thomas.Langbein@zentralklinik.de
- Publication Type:Case Report
- Keywords:
Prostate cancer;
PSMAradioligands;
Salivary glands;
Positronemissiontomography;
Botulinumtoxin;
Xerostomia
- MeSH:
Botulinum Toxins;
Humans;
Metabolism;
Methods;
Middle Aged;
Parotid Gland;
Positron-Emission Tomography and Computed Tomography;
Prostatic Neoplasms;
Salivary Glands;
Xerostomia
- From:Korean Journal of Nuclear Medicine
2018;52(1):80-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
The dose-limiting salivary gland toxicity of ²²⁵Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A ⁶⁸Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.
